top of page

First patient treated in Phase I VXM01 glioblastoma trial

The first patient has been successfully treated in a Phase I clinical trial with Vaximm’s oral T-cell immunotherapy, VXM01, in glioblastoma.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page